About Saba

Saba is an experienced investor in closed-end funds.

Key Facts About Saba

Saba is the world’s largest single investor in closed-end funds, managing a $5.9 billion portfolio that is invested across more than 200 closed-end funds.

Checkbox
Checkbox
Checkbox

Our closed-end fund investment strategy is anchored in protecting shareholder rights, pursuing changes that will return discounted closed-end funds to their full NAV and creating long-term value for shareholders through lower fees and better management.

Checkbox
Checkbox
Checkbox

Our own funds serve as examples of best-in-class corporate governance in the closed-end fund industry. We also have a demonstrated record of advocating for shareholder rights at other funds.

Checkbox
Checkbox
Checkbox

Saba’s Track Record in Closed-End Funds

Saba Capital Income & Opportunities Fund

Saba Capital Income & Opportunities Fund II

Checkbox

Plurality vote standard, equal voting rights, multiple liquidity events for shareholders.

Checkbox

Non-staggered board at BRW.

Checkbox

In May 2024, SABA board approved share repurchase program and 1-for-2 reverse stock split, and de-staggered its board.

CQS Natural Resources Growth & Income PLC

Checkbox

In May 2025, entered standstill with CYN for the trust to tender up to 100% of its shares, enabling shareholders to take a full cash exit if they wish.

Checkbox

The trust also agreed to cut its management fee and raise its annual dividend payout.

Checkbox

Salient Midstream & MLP Fund

Checkbox

In August 2022, reached an agreement to support the fund’s reorganization into a lower fee open-end mutual fund.

Checkbox

Secured distribution paid to all shareholders based on a $300,000 payment by the fund’s investment advisor.

Checkbox

Neuberger Berman High Yield Strategies Fund

Checkbox

In October 2020, reached an agreement with NHS for the fund to tender 25% of its outstanding shares of common stock at a price per share equal to 96% of its NAV per share.

Checkbox

Prior to the announcement, NHS traded at a -8.1% discount to NAV.1 As of Q1 2025, NHS trades at a 1.7% premium to NAV.

Checkbox

Source: Fund documents, Bloomberg. Saba, CQS, Salient and Neuberger Berman: for illustrative purposes only. 1 Bloomberg. Data as of 10/16/2020 close.